Lexaria Bioscience Corp Stock Alpha and Beta Analysis

LEXX Stock  USD 2.13  0.02  0.93%   
This module allows you to check different measures of market premium (i.e., alpha and beta) for all equities such as Lexaria Bioscience Corp. It also helps investors analyze the systematic and unsystematic risks associated with investing in Lexaria Bioscience over a specified time horizon. Remember, high Lexaria Bioscience's alpha is almost always a sign of good performance; however, a high beta will depend on investors' risk tolerance level and may signal increased volatility and potential future overvaluation. Key technical indicators related to Lexaria Bioscience's market risk premium analysis include:
Beta
1.23
Alpha
(0.58)
Risk
4.39
Sharpe Ratio
(0.13)
Expected Return
(0.57)
Please note that although Lexaria Bioscience alpha is a measure of relative return and represented here as a single number, it indicates the percentage above or below your selected benchmark (i.e., Dow Jones Industrial index.) So in this particular case, Lexaria Bioscience did 0.58  worse than the index. Remember, a high alpha is always good. Beta, on the other hand, measures the volatility (or risk) of an investment. It is an indication of Lexaria Bioscience Corp stock's relative risk over its benchmark. Lexaria Bioscience Corp has a beta of 1.23  . As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Lexaria Bioscience will likely underperform. At this time, Lexaria Bioscience's Enterprise Value Over EBITDA is fairly stable compared to the past year. Price Book Value Ratio is likely to rise to 57.61 in 2024, whereas Book Value Per Share is likely to drop 0.08 in 2024.

Enterprise Value

122.2 Million

Alpha is a measure of relative performance on a risk-adjusted basis, while beta measures volatility against the benchmark. The goal is to know if an investor is being compensated for the volatility risk taken. The return on investment might be better than its reference but still not compensate for the assumption of the risk.
  
Check out Lexaria Bioscience Backtesting, Lexaria Bioscience Valuation, Lexaria Bioscience Correlation, Lexaria Bioscience Hype Analysis, Lexaria Bioscience Volatility, Lexaria Bioscience History and analyze Lexaria Bioscience Performance.

Lexaria Bioscience Market Premiums

Investors always prefer to have the highest possible return on investment, coupled with the lowest possible volatility. Lexaria Bioscience market risk premium is the additional return an investor will receive from holding Lexaria Bioscience long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Lexaria Bioscience. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Alpha and beta are two of the key measurements used to evaluate Lexaria Bioscience's performance over market.
α-0.58   β1.23

Lexaria Bioscience expected buy-and-hold returns

Although buy-and-hold investment strategy may not appeal to all investors, it may be used as a good measure of Lexaria Bioscience's Buy-and-hold return. Our buy-and-hold chart shows how Lexaria Bioscience performed over your current time horizon against a typical interest-earning bank account and a selected benchmark.

Lexaria Bioscience Market Price Analysis

Market price analysis indicators help investors to evaluate how Lexaria Bioscience stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading Lexaria Bioscience shares will generate the highest return on investment. By understating and applying Lexaria Bioscience stock market price indicators, traders can identify Lexaria Bioscience position entry and exit signals to maximize returns.

Lexaria Bioscience Return and Market Media

The median price of Lexaria Bioscience for the period between Thu, Aug 29, 2024 and Wed, Nov 27, 2024 is 2.97 with a coefficient of variation of 16.96. The daily time series for the period is distributed with a sample standard deviation of 0.48, arithmetic mean of 2.84, and mean deviation of 0.41. The Stock received a lot of media exposure during the period.
 Price Growth (%)  
       Timeline  
1
Disposition of 200000 shares by Christopher Richard of Lexaria Bioscience at 3.92 subject to Rule 16b-3
09/12/2024
2
Disposition of 200000 shares by Richard Christopher of Lexaria Bioscience at 3.92 subject to Rule 16b-3
09/17/2024
3
Disposition of tradable shares by Downey Gregory of Lexaria Bioscience subject to Rule 16b-3
10/31/2024

About Lexaria Bioscience Beta and Alpha

For many years both, Alpha and Beta indicators are used by professional money managers as critical performance measurement tools across virtually all financial instruments including Lexaria or other stocks. Alpha measures the amount that position in Lexaria Bioscience Corp has returned in comparison to a selected market index or another relevant benchmark. In other words, Alpha is the excess return on an investment relative to the performance of your selected benchmark. Beta, on the other hand, measures the relative risk of your investment.
 2021 2022 2023 2024 (projected)
Days Sales Outstanding288.38282.7726.3525.03
PTB Ratio2.192.2854.8757.61

Lexaria Bioscience Upcoming Company Events

As portrayed in its financial statements, the presentation of Lexaria Bioscience's financial position is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Lexaria Bioscience's leadership is honest, while the outside auditors are strict and uncompromising. Whatever the case, investors should always follow all of Lexaria Bioscience's public filing events to personally review all filings and be reasonable and skeptical to interpret all of the financial statements of Lexaria Bioscience. Please utilize our Beneish M Score to check the likelihood of Lexaria Bioscience's management manipulating its earnings.
12th of April 2024
Upcoming Quarterly Report
View
12th of July 2024
Next Financial Report
View
29th of February 2024
Next Fiscal Quarter End
View
19th of November 2024
Next Fiscal Year End
View
30th of November 2023
Last Quarter Report
View
31st of August 2023
Last Financial Announcement
View

Build Portfolio with Lexaria Bioscience

Your optimized portfolios are the building block of your wealth. We provide an intuitive interface to determine which securities in a portfolio should be removed or rebalanced to achieve better diversification, find the right mix of securities that minimizes portfolio risk for a given return, or maximize portfolio expected return for a given risk level.

Build Diversified Portfolios

Align your risk with return expectations

By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations

Additional Tools for Lexaria Stock Analysis

When running Lexaria Bioscience's price analysis, check to measure Lexaria Bioscience's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Lexaria Bioscience is operating at the current time. Most of Lexaria Bioscience's value examination focuses on studying past and present price action to predict the probability of Lexaria Bioscience's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Lexaria Bioscience's price. Additionally, you may evaluate how the addition of Lexaria Bioscience to your portfolios can decrease your overall portfolio volatility.